Pivotal bioVenture Partners

Pivotal bioVenture Partners

$67,000,000 Venture capital (Series A)
FinSMEs

Inozyme Pharma Raises $67M in Series A2 Financing

Silicon Canals

Swiss startup Oculis secures €13.8M funding to treat ophthalmic diseases

$15,711,870 Venture capital (Series B)
FinSMEs , PE HUB

Oculis Raises CHF15.5M in Extension of Series B Financing

$85,000,000 Venture capital (Series C)
PE HUB , FinSMEs

SutroVax reels in $85 mln Series C

Messaging
PE HUB

| Oculis nabs $20.3 mln Series B

Funding Health
$20,300,000 Venture capital (Series B)
Norðurskautið , FinSMEs

Oculis raises $20.3m Series B round to advance treatment for Ophthalmic Diseases

Funding Health
$65,000,000 Venture capital (Series B)
PE HUB

Iterum grabs $65 mln Series B

Messaging
Xconomy

SutroVax Lands $64M From Roche, Others to Back Vaccine Studies

Health Funding
Venture capital (Series A)
Norðurskautið

Oculis Pharma raises Series A led by Brunnur Ventures and Silfurberg

Health Funding
$40,000,000 Venture capital (Series A)
FinSMEs , VentureWire

Iterum Therapeutics Secures $40M Series A Financing

Funding Health
$22,000,000 Venture capital (Series A)
Xconomy

With $22M Shot of Venture, Sutro Spinout Aims For Better Vaccines

Health